Septic Thrombophlebitis with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia and de novo Resistance to Vancomycin and Daptomycin

Koton, Yael; Or, Zafrir; Bisharat, Naiel

doi:10.4081/idr.2017.7008

Cited by 6 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than 99.9 % of infections are caused by bacteria that are classed as daptomycin susceptible by MIC testing [187]. Additionally, while there are reports of resistance developing during treatment [188,189], this is rare, and in many cases daptomycin treatment fails despite the infection being caused by a bacterium with an MIC classed as susceptible [190][191][192].…”

Section: Daptomycin Tolerancementioning

confidence: 99%

Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort

Ledger

Sabnis

2022

Microbiology

View full text Add to dashboard Cite

The polymyxin and lipopeptide classes of antibiotics are membrane-targeting drugs of last resort used to treat infections caused by multi-drug-resistant pathogens. Despite similar structures, these two antibiotic classes have distinct modes of action and clinical uses. The polymyxins target lipopolysaccharide in the membranes of most Gram-negative species and are often used to treat infections caused by carbapenem-resistant species such as Escherichia coli , Acinetobacter baumannii and Pseudomonas aeruginosa . By contrast, the lipopeptide daptomycin requires membrane phosphatidylglycerol for activity and is only used to treat infections caused by drug-resistant Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. However, despite having distinct targets, both antibiotic classes cause membrane disruption, are potently bactericidal in vitro and share similarities in resistance mechanisms. Furthermore, there are concerns about the efficacy of these antibiotics, and there is increasing interest in using both polymyxins and daptomycin in combination therapies to improve patient outcomes. In this review article, we will explore what is known about these distinct but structurally similar classes of antibiotics, discuss recent advances in the field and highlight remaining gaps in our knowledge.

show abstract

Section: Daptomycin Tolerancementioning

confidence: 99%

Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort

Ledger

Sabnis

2022

Microbiology

View full text Add to dashboard Cite

show abstract

“…[4,5] It is important to recognize the high mortality rate associated with this condition, which has been reported to be as high as 16%. [1,6] The current treatment for LLS is based on empirical antibiotic therapy directed toward the most frequent pathogens. Management of IJV thrombosis is controversial, with some experts recommending anticoagulation as adjuvant treatment.…”

Section: Introductionmentioning

confidence: 99%

“…[ 4 , 5 ] It is important to recognize the high mortality rate associated with this condition, which has been reported to be as high as 16%. [ 1 , 6 ]…”

Section: Introductionmentioning

confidence: 99%

Lemierre-like syndrome after soft tissue infection due to methicillin-resistant Staphylococcus aureus: A case report and literature review

Carreras,

Salcedo,

Ponce-Rosas

et al. 2024

Medicine

View full text Add to dashboard Cite

Rationale: Lemierre-like syndrome (LLS) is characterized by bacteremia, septic thrombophlebitis of the internal jugular vein, and metastatic abscesses. In contrast to classic Lemierre syndrome, sources of infection are not related to oropharyngeal infections, as are frequent soft tissue infections. In recent years, Staphylococcus aureus has been identified as an emergent pathogen that causes this syndrome. The mortality rate of LLS caused by this pathogen is approximately 16%. Timely diagnosis, antibiotic treatment, and infection control are the cornerstones to treat LLS. Anticoagulant therapy as adjuvant treatment remains controversial. Patient concerns: A 31-year-old woman from California, United States (US), was admitted to the emergency room with a history of 2 days of fever and severe throbbing pain in the left cervical region. Thorax and neck CT tomography revealed confluent cavities suggestive of septic embolism in the lungs and a filiform thrombus in the lumen of the left internal jugular vein, with moderate swelling of the soft and muscular tissues. Methicillin-resistant Staphylococcus aureus (MRSA) was isolated from the blood culture. Diagnosis: The thrombus in the internal jugular vein associated with cellulitis in the neck and multiple cavitary lesions in the lungs support the diagnosis of LLS caused by MRSA with septic embolization. Interventions: During treatment, the patient received vancomycin IV for 25 days and returned to the US with linezolid orally. In addition, assisted video-thoracoscopy and bilateral mini-thoracotomy with pleural decortication were performed for infectious source control, where 1700cc of purulent pleural fluid was drained. Outcomes: The patient was discharged with optimal evolution. Lessons: LLS should be suspected in patients with skin and soft tissue infections who develop thrombosis or metastatic infections. MRSA infections should be considered in patients from areas where this pathogen is prevalent.

show abstract

“…Strains with a high level of resistance to daptomycin are rare; however, the use of daptomycin as an alternative to vancomycin is limited due to the associated resistance of certain strains to both antibiotics [2]. Reports of associated resistance in vitro were followed by reports of daptomycin treatment failure in infections caused by VISA strains and vancomycin failure in cases of daptomycin resistance [3][4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Adaptive Laboratory Evolution of Staphylococcus aureus Resistance to Vancomycin and Daptomycin: Mutation Patterns and Cross-Resistance

Gostev

Kalinogorskaya²,

Sopova

et al. 2023

Antibiotics

View full text Add to dashboard Cite

Vancomycin and daptomycin are first-line drugs for the treatment of complicated methicillin-resistant Staphylococcus aureus (MRSA) infections, including bacteremia. However, their effectiveness is limited not only by their resistance to each antibiotic but also by their associated resistance to both drugs. It is unknown whether novel lipoglycopeptides can overcome this associated resistance. Resistant derivatives from five S. aureus strains were obtained during adaptive laboratory evolution with vancomycin and daptomycin. Both parental and derivative strains were subjected to susceptibility testing, population analysis profiles, measurements of growth rate and autolytic activity, and whole-genome sequencing. Regardless of whether vancomycin or daptomycin was selected, most of the derivatives were characterized by a reduced susceptibility to daptomycin, vancomycin, telavancin, dalbavancin, and oritavancin. Resistance to induced autolysis was observed in all derivatives. Daptomycin resistance was associated with a significant reduction in growth rate. Resistance to vancomycin was mainly associated with mutations in the genes responsible for cell wall biosynthesis, and resistance to daptomycin was associated with mutations in the genes responsible for phospholipid biosynthesis and glycerol metabolism. However, mutations in walK and mprF were detected in derivatives selected for both antibiotics.

show abstract

Septic Thrombophlebitis with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia and de novo Resistance to Vancomycin and Daptomycin

Cited by 6 publications

References 21 publications

Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort

Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort

Lemierre-like syndrome after soft tissue infection due to methicillin-resistant Staphylococcus aureus: A case report and literature review

Adaptive Laboratory Evolution of Staphylococcus aureus Resistance to Vancomycin and Daptomycin: Mutation Patterns and Cross-Resistance

Contact Info

Product

Resources

About